Previous 10 |
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve...
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 th starting at 12:00 pm ET in New Y...
Thinly traded Allakos (NASDAQ: ALLK ) slumps 11% premarket on light volume on the heels of new data from a Phase 2 clinical trial evaluating lead drug AK002 in patients with urticaria (hives). More news on: Allakos, Healthcare stocks news, Stocks on the move, Read more .....
-- 82% (9 of 11) response rate in patients with cholinergic urticaria -- -- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the t...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...